Page 1278 - Hematology_ Basic Principles and Practice ( PDFDrive )

1124 Part VII Hematologic Malignancies

REFERENCES 8. Karow A, Nienhold R, Lundberg P, et al: Mutational profile of childhood
myeloproliferative neoplasms. Leukemia 29(12):2407–2409, 2015.
1. Barbui T, Finazzi G, Carobbio A, et al: Development and validation 9. Passamonti F, Thiele J, Girodon F, et al: A prognostic model to predict
of an International Prognostic Score of thrombosis in World Health survival in 867 World Health Organization-defined essential throm-
Organization-essential thrombocythemia (IPSET-thrombosis). Blood bocythemia at diagnosis: a study by the International Working Group
120(26):5128–5133, 2012. on Myelofibrosis Research and Treatment. Blood 120(6):1197–1201,
2. Barbui T, Vannucchi AM, Buxhofer-Ausch V: Practice-relevant revi- 2012.
sion of IPSET-thrombosis based on 1019 patients with WHO-defined 10. Quintás-Cardama A, Kantarjian H, Manshouri T, et al: Pegylated inter-
essential thrombocythemia. Blood Cancer J. 5:e369, 2015. feron alfa-2a yields high rates of hematologic and molecular response
3. Barosi G, Mesa R, Finazzi G, et al: Revised response criteria for poly- in patients with advanced essential thrombocythemia and polycythemia
cythemia vera and essential thrombocythemia: an ELN and IWG-MRT vera. J Clin Oncol 27:5418, 2009.
consensus project. Blood 121(23):4778–4781, 2013. 11. Rumi E, Pietra D, Ferretti V, et al: JAK2 or CALR mutation status
4. Carobbio A, Thiele J, Passamonti F, et al: Risk factors for arterial and defines subtypes of essential thrombocythemia with substantially differ-
venous thrombosis in WHO-defined essential thrombocythemia: an ent clinical course and outcomes. Blood 123(10):1544–1551, 2014.
international study of 891 patients. Blood 117:5857, 2011. 12. Srour SA, Devesa SS, Morton LM, et al: Incidence and patient survival
5. Cortelazzo S, Finazzi G, Ruggeri M, et al: Hydroxyurea for patients with of myeloproliferative neoplasms and myelodysplastic/myeloproliferative
essential thrombocythemia and a high risk of thrombosis. N Engl J Med neoplasms in the United States, 2001-12. Br J Haematol 2016. doi:
332:1132, 1995. 10.1111/bjh.14061.
6. Gisslinger H, Gotic M, Holowiecki J, et al: Anagrelide compared with 13. Tapper W, Jones AV, Kralovics R, et al: Genetic variation at MECOM,
hydroxyurea in WHO-classified essential thrombocythemia: the ANAHY- TERT, JAK2 and HBS1L-MYB predisposes to myeloproliferative neo-
DRET Study, a randomized controlled trial. Blood 121(10):1720–1728, plasms. Nat Commun 6:6691, 2015. doi: 10.1038/ncomms7691.
2013. 14. Thiele J, Kvasnicka HM, Müllauer L, et al: Essential thrombocythemia
7. Harrison CN, Campbell PJ, Buck G, et al: United Kingdom Medical versus early primary myelofibrosis: a multicenter study to validate the
Research Council Primary Thrombocythemia 1 Study. Hydroxyurea WHO classification. Blood 117:5710–5718, 2011.
compared with anagrelide in high-risk essential thrombocythemia. N
Engl J Med 353:33, 2005.